Before surgery, each animal was deeply anesthetized with an intramuscular injection of ketamine (8 mg/kg) and xylazine (0.1 mL/kg). Three 11-0 nylon sutures (Serag Wiessner, Naila, Germany) were placed intrastromally with two stromal incursions extending over 120° of corneal circumference each. The outer point of suture placement was chosen near the limbus, and the inner suture point was chosen near the corneal center equidistant from the limbus, to obtain standardized angiogenic responses. Sutures were left in place for the duration of the experiment. The systemic treatment group received bevacizumab intraperitoneally on the day of surgery and 3 days later (5 mg/kg in saline solution, according to the manufacturer’s instruction). Control mice received an equal volume and concentration of a human IgG1k-isotype control (Southern Biotech) or an equal volume of saline solution. After 7 days, the mice were killed. In the long-term treatment group, the mice received 5 mg/kg bevacizumab in saline solution on the day of surgery, and on days 3, 6, 9, and 12. Control mice received an equal volume of saline solution. After 14 days, the mice were killed. For topical treatment, the central 2 mm of the corneal epithelium was scraped off before suturing, and the mice received bevacizumab (5 mg/mL; four times daily; according to off-label treatments and the literature) in eye drops for 5 days. Control mice received an equal volume of saline solution. The mice were killed after 5 days.